How Long Lorazepam Stays in Urine and Why It Varies

Lorazepam is typically detectable in urine for about six days after a single standard dose, though the actual window can be shorter or longer depending on your metabolism, kidney function, age, and even which type of drug test is used. In a controlled study where volunteers took a single 2.5 mg tablet, urine samples tested positive for lorazepam out to 144 hours, with concentrations peaking around 24 hours after the dose. That six-day figure is a useful benchmark, but the biology behind it is worth understanding because the real-world range can shift meaningfully in either direction.

How Your Body Handles Lorazepam

Lorazepam belongs to the benzodiazepine family, but it takes a somewhat unusual metabolic path compared to many of its relatives. Instead of being broken down by the liver’s oxidative enzymes (the cytochrome P450 system that processes drugs like diazepam and alprazolam), lorazepam is cleared primarily through a process called glucuronidation. The liver attaches a sugar molecule (glucuronic acid) to lorazepam, converting it into lorazepam glucuronide, an inactive compound that the kidneys then flush out in urine.¹ Roughly 64% of a dose ends up excreted in urine as this glucuronide conjugate, with less than 1% showing up in feces.²

The elimination half-life of lorazepam, meaning the time it takes for half of the drug to leave your bloodstream, ranges from about 8 to 25 hours in adults.³ That wide range matters because it means some people clear the drug two to three times faster than others. Blood levels and urine levels are not the same thing, though. Even after lorazepam has mostly left the bloodstream, its metabolites continue to wash out through the kidneys for days, which is why urine detection windows stretch well beyond what the half-life alone would suggest.

What a Single Dose Looks Like in Urine

The clearest picture of how long lorazepam lingers comes from a study designed specifically to map its detection window. Researchers gave three volunteers a single 2.5 mg oral dose and collected urine samples for 144 hours (six days). Lorazepam was detectable throughout that entire period, though concentrations dropped steeply after the first day. The peak urine concentration appeared at about 24 hours post-dose and ranged from 411 to 880 ng/mL. By the end of the six-day collection window, levels had fallen to just 2 to 4 ng/mL.⁴

Those tail-end concentrations are important because they sit right at the edge of what many standard drug screens can reliably pick up. Whether the test flags a sample as positive at that point depends on the testing method and its sensitivity threshold. In practical terms, if you took a single dose and are being screened several days later, the result could go either way depending on the lab’s equipment and cutoff values.

Chronic Use and Drug Accumulation

A single 2.5 mg dose and weeks of daily use produce very different urine profiles. When lorazepam is taken repeatedly, each new dose adds to the residual amount still being processed from previous doses. Because the half-life can reach 25 hours in some people, a once-daily regimen means the next dose arrives before the previous one is fully eliminated. Over time, this leads to a steady-state buildup of both lorazepam and its glucuronide metabolite in the body.

The practical result is that someone who has been taking lorazepam daily for weeks or months will have a longer detection window in urine than someone who took a single tablet. The six-day figure from the single-dose study is a floor, not a ceiling, for chronic users. Detection times of one to two weeks or more after the last dose are plausible, though published data on exact windows for long-term users are sparse. The key variable is how much drug has accumulated in body tissues, which depends on the dose, how long you’ve been taking it, and your individual clearance rate.

How Age Affects Clearance

Older adults tend to clear lorazepam more slowly than younger people, but the difference is smaller than many expect. A study comparing young and elderly subjects found that clearance dropped by about 22% in the older group, from roughly 0.99 mL/min/kg to 0.77 mL/min/kg. Interestingly, the elimination half-life itself was not significantly different between the two groups (about 14 hours in the young versus about 16 hours in the elderly).⁵ Part of the difference in clearance was explained by higher rates of cigarette smoking in the younger group rather than age alone. Still, older adults should expect lorazepam to linger slightly longer in their systems, which could add a day or so to the urine detection window compared to a healthy younger person taking the same dose.

Newborns are a different story entirely. In neonates, the rate of glucuronidation is immature, and the apparent half-life of lorazepam runs three to four times longer than in adults.⁶ This isn’t directly relevant to urine drug screening for most readers, but it underscores how dramatically the body’s ability to process lorazepam can change at the extremes of age.

Kidney Problems Slow Excretion

Since the kidneys are responsible for flushing out lorazepam glucuronide, impaired kidney function can significantly extend how long the metabolite hangs around. In people with severe renal impairment, the glucuronide conjugate accumulates in the blood for days after a single dose because the kidneys cannot clear it efficiently.⁷ The liver’s ability to convert lorazepam into its glucuronide metabolite stays intact; the bottleneck is purely on the excretion side.

Even hemodialysis does not dramatically speed things up. One study found that only about 8% of intact lorazepam was removed during a six-hour dialysis session, though around 40% of the glucuronide conjugate was cleared in that same window.² For someone with compromised kidneys, the practical upshot is that lorazepam metabolites will remain detectable in urine substantially longer than in someone with normal renal function.

Why Liver Disease Matters Less Than You Might Think

Here is where lorazepam diverges from many other benzodiazepines. Drugs like diazepam, chlordiazepoxide, and midazolam are broken down by the liver’s oxidative pathways, which are significantly impaired in liver cirrhosis. Lorazepam’s reliance on glucuronidation instead of oxidation gives it a meaningful clinical advantage. Research has shown that glucuronidation remains largely unaffected in alcoholic liver cirrhosis and cirrhosis from other causes, meaning lorazepam concentrations are unlikely to differ substantially between people with liver disease and healthy individuals.⁸ This is one reason lorazepam is often preferred for managing alcohol withdrawal in patients with liver problems.

That said, “largely unaffected” does not mean completely unaffected. In end-stage liver disease with significant organ failure, all metabolic processes slow down. But for the purposes of urine detection timing, moderate liver impairment alone is not a major variable with lorazepam the way it would be with diazepam.

Drug Interactions That Change the Timeline

Because lorazepam is processed by specific glucuronidation enzymes (mainly UGT2B7 and UGT2B15), any other medication that competes for or inhibits those enzymes can slow its clearance.¹ The best-documented example is valproic acid (often prescribed as Depakote for seizures or bipolar disorder). When valproate is taken alongside lorazepam, lorazepam’s clearance through glucuronidation drops by roughly 31%, and trough blood concentrations rise by a similar margin.⁹

A 31% reduction in clearance is large enough to extend both the duration of the drug’s effects and the window during which it shows up in urine. If you are taking valproate or another medication that inhibits glucuronidation, lorazepam will stay in your system longer than the standard estimates would predict. Probenecid, a drug used for gout, is another known inhibitor of glucuronidation and could have a similar effect, though the interaction has been less formally studied with lorazepam specifically.

Does Genetics Play a Role?

Given that specific UGT enzymes handle lorazepam’s metabolism, it is reasonable to wonder whether genetic variations in those enzymes create fast and slow metabolizers, as happens with many other drugs. The answer, at least for the most studied variant, is surprisingly no. A study examining UGT2B7 genetic polymorphisms found no significant differences in lorazepam clearance between people carrying different versions of the gene.¹⁰ This does not rule out the possibility that other genetic factors (perhaps involving UGT2B15 or UGT2B4) could contribute to individual variation, but it does suggest that the wide range in lorazepam’s half-life is driven more by acquired factors like age, kidney function, and concurrent medications than by inherited enzyme activity. The research here is thinner than for the cytochrome P450 pharmacogenomics that get a lot of attention in personalized medicine, so lorazepam’s metabolic genetics remain an area where evidence is incomplete.

Why Some Drug Tests Miss Lorazepam Entirely

One of the most practically important facts about lorazepam and urine testing is that not all screening tests detect it equally well. Standard workplace and clinical drug panels typically use immunoassay-based screening as a first pass. These tests work by using antibodies that react with benzodiazepines or their metabolites. The problem is that different immunoassay kits have very different sensitivities to lorazepam. A comparison of two commercial screening methods found that one kit (the ARK HS Benzodiazepine II Assay) showed very high sensitivity for lorazepam, with cross-reactivity above 100%, while another widely used kit (the EMIT II Plus immunoassay) had cross-reactivity below 50%, meaning it could miss lorazepam entirely in samples where it was genuinely present.¹¹

This means that whether lorazepam is flagged on a urine drug screen depends partly on which assay the lab happens to use. A person who genuinely took lorazepam might receive a negative screening result simply because the test was not well-suited to detecting it. Conversely, a more sensitive assay might pick up traces days after the drug would have been missed on a less sensitive platform.

There is also a technical wrinkle in how labs prepare urine samples for confirmatory testing. Since most lorazepam in urine exists as the glucuronide conjugate rather than the parent drug, labs often need to treat the sample with an enzyme called beta-glucuronidase to convert the metabolite back into lorazepam before running confirmation by gas chromatography-mass spectrometry (GC/MS).¹² Labs that skip this step or perform it inadequately may underestimate or miss lorazepam on confirmation, creating a scenario where even an advanced analytical method fails to catch it.

False Positives and What Else Triggers Benzodiazepine Screens

While the focus of this article is on true positives, it is worth knowing that benzodiazepine immunoassays are also prone to false positives from unrelated medications. A retrospective chart analysis of over 500 records found that out of 160 results initially flagged as positive for benzodiazepines and later determined to be false positives on confirmatory GC/MS, 26 were associated with a prescription for sertraline (Zoloft).¹³ If you are on sertraline and test positive on a preliminary benzodiazepine screen, that result deserves confirmatory testing before anyone draws conclusions.

Other medications reported to interfere with benzodiazepine immunoassays in various studies include the antihistamine oxaprozin and certain NSAIDs, though the evidence is scattered and kit-dependent. The takeaway is that immunoassay results for benzodiazepines in general, and lorazepam in particular, carry meaningful rates of both false positives and false negatives. A single screening result without confirmation is unreliable in either direction.

Putting the Timeline Together

Given all these variables, here is a rough framework for how long lorazepam is likely to show up in urine across different scenarios:

Single low dose, healthy adult: Up to about 6 days on a sensitive test, possibly only 2 to 3 days on a less sensitive immunoassay.
Chronic daily use: One to two weeks or longer after the last dose, depending on the accumulated body burden and individual clearance rate.
Kidney impairment: The glucuronide metabolite accumulates, potentially extending detection beyond what would be expected based on dose and duration alone.
Concurrent valproate use: Roughly a 30% reduction in clearance, which could add a day or more to the detection window after a single dose and proportionally more after chronic use.
Older adults: Modestly slower clearance, likely adding a day or so compared to a younger person taking the same dose.

These estimates assume a test sensitive enough to detect lorazepam in the first place. On an immunoassay with poor lorazepam cross-reactivity, the practical detection window could be meaningfully shorter simply because the test stops registering the drug at concentrations where a better assay still would. If the testing context matters to you, whether for employment screening, pain management compliance monitoring, or forensic investigation, the analytical method used is as relevant as your biology.

Lorazepam Versus Other Benzodiazepines in Urine Testing

Lorazepam occupies an unusual middle ground among benzodiazepines for urine detection. Short-acting drugs like triazolam and midazolam leave the body faster and have narrower detection windows. Long-acting drugs like diazepam, which is metabolized to active compounds that themselves have half-lives of 40 to 100 hours, can be detected in urine for weeks after the last dose. Lorazepam sits between these extremes, with its moderate half-life and single-step glucuronidation pathway keeping it detectable for days but not weeks after a single dose.

What makes lorazepam particularly tricky in a testing context, though, is the immunoassay sensitivity issue described earlier. Many standard benzodiazepine screens were optimized to detect the metabolites of diazepam (nordiazepam and oxazepam), which are the most commonly encountered benzodiazepines in older drug-test validation studies. Lorazepam’s glucuronide metabolite is structurally different enough that some assays perform poorly with it, even when the drug is present at concentrations that would easily flag diazepam. The researchers who compared immunoassay kits concluded that liquid chromatography with tandem mass spectrometry (LC-MS/MS) was the most reliable method for detecting lorazepam in forensic and clinical contexts.⁴ Not every lab uses this technology for routine screening, but it is increasingly available and is the gold standard when accurate lorazepam detection matters.